NCT07215949 - Zilucoplan for Severe gMG Exacerbations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

April 1, 2028

Conditions

Generalized Myasthenia Gravis (gMG)

Interventions

DRUG

Zilucoplan®

Subcutaneous injections of zilucoplan will be administered daily. The dose is dependent on the body weight of the patient. Each patient will receive a kit with prefilled syringes.

Trial Locations (1)

43210

The Ohio State University, Columbus